To figure out whether SEVO may promote AD-associated neurodegeneration through activation of NLRP3 inflammasome, we did five interferences with NLRP3 inhibitor, MCC950, with an interval of 2 h in between, starting immediately before the SEVO/Air exposure (SEVO+MCC). The gene discussed is NLRP3; the disease is Alzheimer disease.